Bartosz Wasąg
Gdańsk Medical University
43 Papers
123 Citations
Bartosz Wasąg is an academic researcher from Gdańsk Medical University. The author has contributed to research in topics: Familial hypercholesterolemia & Butyrylcholinesterase. The author has an hindex of 12, co-authored 43 publications.
Chat about Author
Papers
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
Rafal Dziadziuszko,Egbert F. Smit,Urania Dafni,Juergen Wolf,Bartosz Wasąg,Wojciech Biernat,Stephen P. Finn,Roswitha Kammler,Zoi Tsourti,Manuela Rabaglio,Barbara Ruepp,H. Roschitzki-Voser,Rolf A. Stahel,Enriqueta Felip,Solange Peters +14 more
TL;DR: Afatinib did not show the expected potential for disease control in NSCLC, but more than half of the patients in the full cohort achieved disease control at 12 weeks.
139
A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib
Andrzej Mital,Anna M. Piskorz,Krzysztof Lewandowski,Bartosz Wasąg,Janusz Limon,Andrzej Hellmann +5 more
TL;DR: This data indicates that suppression of tyrosine kinase in mastocytosis results in down-regulation in the prognosis of MCL patients and the need for further cytoreductive therapy to treat this disease.
52
Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer’s Disease—Could BCHE Genotyping Be Helpful in Alzheimer’s Therapy?
Jacek Jasiecki,Bartosz Wasąg +1 more
- 09 Oct 2019
TL;DR: SNPs localized outside of the coding sequence, in 5’UTR (rs1126680) and/or intron 2 (rs55781031) of the BCHE gene, but not solely K-variant alteration (p.A539T) itself, are responsible for reduced enzyme activity, which is suspected to be associated with deleterious changes in cognitive decline in patients treated with ChEIs.
47
The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.
Paweł Krawczyk,Rodryg Ramlau,Joanna Chorostowska-Wynimko,Tomasz Powrózek,Marzena Anna Lewandowska,Janusz Limon,Bartosz Wasąg,Juliusz Pankowski,Jerzy Kozielski,Ewa Kalinka-Warzocha,Aleksandra Szczesna,Kamila Wojas-Krawczyk,Michal Skronski,Rafal Dziadziuszko,Paulina Jaguś,Ewelina Antoszewska,Justyna Szumiło,Bożena Jarosz,Aldona Woźniak,Wojciech Jóźwicki,Wojciech Dyszkiewicz,Monika Pasieka-Lis,Dariusz M. Kowalski,Maciej Krzakowski,Jacek Jassem,Janusz Milanowski +25 more
TL;DR: Cytological and small biopsy samples with low content of tumor cells and specimens from metastatic lesions are a sufficient source for EGFR mutation testing in NSCLC patients and the incidence of EGFR gene mutations was similar to those reported in other Caucasian populations.
38
New Insights into Butyrylcholinesterase Activity Assay: Serum Dilution Factor as a Crucial Parameter.
Joanna Jońca,Monika Żuk,Bartosz Wasąg,Anna Janaszak-Jasiecka,Krzysztof Lewandowski,Bartosz Wielgomas,Krzysztof Waleron,Jacek Jasiecki +7 more
TL;DR: It is shown that a 400-fold dilution of serum and 5mM S-butyrylthiocholine iodide can be successfully used for the accurate measurement of BChE activity in human serum and the observed inhibitory effect is dependent on serum dilution factor used in the assay.